JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
JCR Pharmaceuticals Co., Ltd. reported a significant decline in their financial performance for the first half of FY2024, with net sales dropping by 31.4% and a net loss per share compared to the same period last year. Despite maintaining dividend forecasts, the company revealed changes in its subsidiary structure, excluding Mycenax Biotech Inc. from consolidation.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.